Letters

Filter By:

Article Type
Year
  • In a phase II, randomized, placebo-controlled, double-blind cross-over trial, Jama et al. show that delivery of short-chain fatty acids via acetylated and butyrylated high-amylose maize starch (HAMSAB) supplementation result in a clinically relevant reduction in 24-hour systolic blood pressure in patients with essential hypertension.

    • Hamdi A. Jama
    • Dakota Rhys-Jones
    • Francine Z. Marques
    Letter
  • Using data from the MONICA/KORA registry, Chen et al. show that the risk of heat-related non-fatal myocardial infarction was significantly elevated in patients receiving anti-platelet medication and beta-receptor blockers compared with non-users, and the effect of the medications was stronger in younger patients, with lower prevalence of pre-existing cardiovascular disease, compared with older patients.

    • Kai Chen
    • Robert Dubrow
    • Alexandra Schneider
    Letter
  • Fractional flow reserve (FFR) is the current gold standard method to quantify coronary blood flow (CBF) changes in coronary artery disease. In a large comparative study on 203 diseased arteries, Aubiniere-Robb et al. analyzed the degree of concordance between fractional and absolute CBF reduction and identified the FFR areas with high discordance. Patients with those FFR values may benefit from the additional absolute CBF measures.

    • Louise Aubiniere-Robb
    • Rebecca Gosling
    • Paul D. Morris
    Letter Open Access
  • Hansmann et al. show that serial intravascular infusions of conditioned media produced by allogenic umbilical cord mesenchymal stem cells markedly improved the clinical features of a young child with severe pulmonary arterial hypertension. The multi-omic approach analyzing the transcriptome and the proteome of these stem cells isolated from four donors provides initial insight into their beneficial paracrine function.

    • Georg Hansmann
    • Philippe Chouvarine
    • Ralf Hass
    Letter Open Access
  • Snellings et al. show that an identical PIK3CA mutation is found in both developmental venous anomalies (DVAs) and associated cerebral cavernous malformations (CCMs). However, an activating MAP3K3 mutation appears only in CCMs, supporting a mechanism where DVAs develop as the result of a PIK3CA mutation.

    • Daniel A. Snellings
    • Romuald Girard
    • Douglas A. Marchuk
    Letter
  • Honigberg and colleagues analyzed the frequency of depressed mood in conjunction with polygenic risk scores for coronary artery disease (CAD), type 2 diabetes (T2D) and atrial fibrillation in the UK Biobank and showed that depressed mood was independently associated with a lower risk of CAD and T2D across the cardiometabolic polygenic risk spectrum.

    • Michael C. Honigberg
    • Yixuan Ye
    • Pradeep Natarajan
    Letter
  • Cerebral venous thrombosis (CVT) is a rare life-threatening disease of unknown etiology. Stegner et al. show that aberrant platelet activation through cooperative signaling of CLEC-2 and GPIIb/IIIa receptors triggers foudroyant CVT in mice and shed light on the molecular pathways of the disease pathogenesis.

    • David Stegner
    • Vanessa Göb
    • Bernhard Nieswandt
    Letter Open Access